Prelude Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Prelude Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-39,349	Closed	-$392K	–	1267
2025 Q2	$392K	Buy	39,349 +23,005	+141%	+$185K	0.04%	515
2025 Q1	$97.6K	Buy	16,344 +5,736	+54%	+$42.1K	0.01%	1044
2024 Q4	$81.5K	Sell	10,608 -3,269	-24%	-$28.1K	0.01%	1115
2024 Q3	$142K	Buy	+13,877	New	+$212K	0.01%	1119
2024 Q2	–	Sell	-17,428	Closed	-$238K	–	1360
2024 Q1	$238K	Buy	+17,428	New	+$190K	0.01%	1015
2021 Q1	–	Sell	-6,478	Closed	-$219K	–	1680
2020 Q4	$219K	Buy	+6,478	New	+$172K	0.01%	1068

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's ITOS Position: Q3 2025 in Review

Prelude Capital Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 39,349 shares — an estimated $392K sold.

Prelude Capital Management first reported a position in ITOS in Q4 2020 and held it in 6 quarters. The position peaked at $392K in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Prelude Capital Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 39,349 iTeos Therapeutics shares in Q3 2025, an estimated $392K.
Prelude Capital Management first reported a position in iTeos Therapeutics in Q4 2020 and held it in 6 quarters.
Prelude Capital Management's iTeos Therapeutics position peaked at $392K in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.